Headlands Research Deepens Diversity and Expands Network with Launch of Metro Detroit–Based Clinical Trial Site

Headlands Research Detroit focuses on clinical trials of priority diseases and conditions for the local population

SAN FRANCISCO--(BUSINESS WIRE)--Headlands Research, a leading multinational network of clinical trial sites, today announced that it recently launched a metro Detroit–based clinical research site, expanding clinical trial access to a large population that contributes to the overall diversity and representativeness of Headlands Research’s site network. Headlands Research Detroit is the second site to open following last year’s announcement of a multiyear initiative to launch several diversity-focused sites.

“At Headlands Research, one of our primary missions is to increase access to clinical trials for a broader range of the population so our research results reflect the people most affected by a disease or condition,” said Cathy Collins, CEO of Headlands Research. “Adding this site and its skilled, experienced staff to our network allows us to ensure our research helps reduce health disparities by reaching a more inclusive group of people who are traditionally underrepresented in clinical research.”

Research at the Detroit site is led by Principal Investigators Dr. David Strong and Dr. Sophie Toya, with Patrick Keating as Site Director. Dr. Strong is board certified in emergency medicine with a master’s degree in neuroscience. He has a focus on community health and currently applies his extensive medical experience to research in vaccine effectiveness, immunomodulators, and metabolic syndrome. Dr. Toya is board certified in pulmonology and has led clinical trials on pathologies such as COPD, asthma, and lung cancer. She is passionate about sharing her expertise through teaching, mentorship, and publishing. The combined clinical expertise of Dr. Strong and Dr. Toya provides the foundation necessary to lead research that produces high-quality data in the therapeutic areas currently being studied at the site, such as Alzheimer’s disease, vaccines, women’s health, asthma, COPD, type 2 diabetes, and more.

“As a proud Southeast Michigan native, I’ve dedicated my career to making excellent medical care available to the local region,” said Dr. Strong. “Through our work at Headlands Research Detroit, I’m excited to advance the clinical trial process and bring innovative and promising treatments to the people who need them most.”

“We have a vibrant, ambitious clinical development team who works hard to make a difference in the lives of our patients and community,” added Dr. Toya. “I look forward to the value our commitment to research and expertise across therapeutic areas will bring to the Headlands Research multinational network.”

To learn more about Headlands Research and its extensive network of research sites, visit https://headlandsresearch.com, reach out to [e-mail], or follow the company on LinkedIn.

About Headlands Research

Headlands Research is a multinational integrated clinical trial site organization with a mission to profoundly change the clinical trials process. Its group of exceptional sites focuses on large-volume recruitment of diverse and specialty patient populations while delivering the highest quality data. Headlands Research’s principal investigators are proven industry leaders in their fields with expertise in a wide variety of indications. Utilizing expert recruitment strategies and access to diverse patients through its site databases and physician partnerships, Headlands Research has successfully completed more than 5,000 clinical trials. Additional information about the company is available at www.headlandsresearch.com.